Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Apr 8;8(6):958-961.
doi: 10.1002/ccr3.2721. eCollection 2020 Jun.

Epstein-Barr Virus-related mucocutaneous ulcer lymphoma associated with Crohn's disease, treated with monoclonal antibody anti-CD30

Lydia Montes  1 , Estelle Tredez  2 , Clara Yzet  3 , Caroline Delette  1 , Denis Chatelain  2 , Delphine Lebon  1 , Mathurin Fumery  3 , Jean-Pierre Marolleau  1
Affiliations
Case Reports

Epstein-Barr Virus-related mucocutaneous ulcer lymphoma associated with Crohn's disease, treated with monoclonal antibody anti-CD30

Lydia Montes et al. Clin Case Rep. .

Abstract

Epstein-Barr virus-related mucocutaneous ulcer lymphoma is a rare entity promoted by immunosuppression. It is less described in inflammatory bowel diseases, and mostly these are refractory diseases. CD30 acts to Epstein-Barr virus (EBV) local proliferation and thus could be an interesting target. Brentuximab vedotin could become a new helpful tool.

Keywords: CD30; brentuximab vedotin; epstein‐barr virus; immunosuppression; lymphoma.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

Figure 1
Figure 1
Colonoscopy images: large and deep ulcerations and pseudo‐membranes before treatment (images above). macroscopical improvement after treatment with Brentuximab vedotin (images below)
Figure 2
Figure 2
Rectal biopsies at diagnosis: large lymphoid cells seen in HES coloration (blue arrow) (×20 magnification); large lymphoid cells marked by CD30 antibody (black arrows); lymphoid cells nucleus marked by EBER probe in in situ hybridation, highlighting EBV presence (white arrows) (×10 magnification)
Figure 3
Figure 3
Rectal biopsies after treatment with Brentuximab vedotin: disappearance of large lymphoid cells in HES coloration (×20 magnification); clearance of lymphoid cells marked by CD30 antibody (×20 magnification); disappearance of lymphoid cells nucleus marked by EBER probe in in situ hybridation (×10 magnification)
See this image and copyright information in PMC

References

    1. Dojcinov SD, Venkataraman G, Raffeld M, Pittaluga S, Jaffe ES. EBV positive mucocutaneous ulcer–a study of 26 cases associated with various sources of immunosuppression. Am J Surg Pathol. 2010;34(3):405‐417. - PMC - PubMed
    1. Hart M, Thakral B, Yohe S, et al. EBV‐positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder. Am J Surg Pathol. 2014;38(11):1522‐1529. - PubMed
    1. Dierickx D, Habermann TM. Post‐transplantation lymphoproliferative disorders in adults. N Engl J Med. 2018;378(6):549‐562. - PubMed
    1. Nelson AA, Harrington AM, Kroft S, Dahar MA, Hamadani M, Dhakal B. Presentation and management of post‐allogeneic transplantation EBV‐positive mucocutaneous ulcer. Bone Marrow Transplant. 2016;51(2):300‐302. - PubMed
    1. Vase MØ, Maksten EF, Bendix K, et al. Occurrence and prognostic relevance of CD30 expression in post‐transplant lymphoproliferative disorders. Leuk Lymphoma. 2015;56(6):1677‐1685. - PubMed

Publication types

LinkOut - more resources